|Primary analysis complete
|Study Start Date:
|Study Made Public:
A Phase I safety and immunogenicity trial of an Alphavirus Replicon HIV subtype C gag vaccine (AVX101, AlphaVax, Inc.) in healthy HIV-1 uninfected adult volunteers
HVTN 040 is a Phase I clinical trial to evaluate the safety and immunogenicity of the alphavirus replicon HIV subtype C gag vaccine, AVX101.
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.